C3i is attending the 10th Canadian Cancer Immunotherapy Consortium this week!
C3i will attend the 10th Canadian Cancer Immunotherapy Consortium in Montreal from December 13th to 15th to engage with researchers, clinicians and industry leaders in the Cancer Immunotherapy field. Danielle de Verteuil, for the Biomarker & Diagnostics unit, and Arnaud Deladeriere for the cGMP Manufacturing unit, will be representing and promoting C3i for its outstanding capacity to help biotech companies and pharmas to achieve their objectives.
From April 7 to 9, 2026, C3i took part in the 4th Pan-Canadian Strategic Forum on Cell and Gene Therapies, organized by CellCAN at the Sheraton Laval & Convention Center. The event brought together key players in the sector, including scientists, innovators, and partners from the cell and gene therapy biomanufacturing ecosystem, around a […]
From March 29 to 31, 2026, C3i participated in the Summit for Cancer Immunotherapy (Summit4CI), organized by BioCanRx in Vancouver. This annual event brings together scientists, clinicians, industry leaders, and patient advocates committed to advancing immuno-oncology. At the event, Jamie Sharp, Director of Business Development at C3i, represented the organization to engage with the […]
Regulatory inspections represent a critical validation of manufacturing quality systems in cell and gene therapy. These inspections assess not only whether procedures exist, but whether they are effectively implemented and consistently followed. For advanced therapy manufacturers, inspection readiness reflects the strength, maturity, and reliability of the entire Quality Assurance framework. At C3i, inspection readiness begins […]
We use cookies for necessary website functionality, analytics and marketing. You can find more information about our cookie policy in our privacy policy notice.
Technical Bulletin
Receive our quarterly technical bulletin and more. Subscribe
